Rentschler Biopharma in Laupheim receives ISO 27001 certification for information security management
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), today announced that its global Information Security Management System (ISMS) has been certified according to ISO 27001 for its Laupheim site. This globally recognized certification confirms Rentschler Biopharma's commitment to protecting sensitive data and complying with legal and regulatory requirements.
The ISO 27001 certification was awarded following successful audits by DEKRA Certification GmbH. Gunnar Voss von Dahlen, Chief Financial Officer (CFO) and member of the Executive Committee, accepted the certificate at a ceremony in Laupheim on September 9th. He said: “With successful ISO 27001 certification, we have passed a first high bar and proven that our information security management meets top standards. This is something we are very proud of. Our clients, partners and employees can rest assured that their sensitive data and projects are in the best of hands. 'Reliability you can trust' is not just a promise, it is the cornerstone of our work at Rentschler Biopharma.”
Rentschler Biopharma started its first information security assessments in 2016, followed by the systematic development of the company’s Information Security Management System. Today, this system is in place at all three of the company's sites in Laupheim, Germany; Milford, USA and Stevenage, UK and, accordingly, all of the company's employees are regularly trained. By aligning its ISMS with the ISO 27001 internationally recognized framework, Rentschler Biopharma ensures a structured approach to risk mitigation and employs robust security controls to effectively protect company data.
“At a time when cyber threats are becoming increasingly complex, especially in the biopharmaceutical industry, the protection of sensitive data is of crucial importance. ISO 27001 certification for our site in Laupheim is a significant milestone that demonstrates our commitment to a structured and well-planned information security management system,” explained Gerrick Rodrigues, Global Head of IT. “The implementation of the ISMS was a comprehensive global project involving all Rentschler Biopharma sites and more than 70 dedicated colleagues. This success would not have been possible without the hard work and dedication of our IT team and the support of all departments.”